Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Biotech
Volatile day for CAR-T biotechs after FDA reveals safety review
CAR-T therapy biotechs had a tough day at the market after the FDA announced a probe into secondary cancers that can occur after the treatments.
Annalee Armstrong
Nov 28, 2023 4:35pm
'Special' CAR-T target works in solid tumors, but limits remain
Nov 28, 2023 9:00am
CRISPR Therapeutics laid off staff a week after positive AdComm
Nov 22, 2023 1:36pm
Flagship launches first UK biotech Quotient Therapeutics
Nov 21, 2023 6:00am
Astellas finds underlying liver issues in gene therapy deaths
Nov 16, 2023 7:12am
Gilead hands Arcellx $285M to expand BCMA cell therapy deal
Nov 15, 2023 10:00am
More News
Selecta fuses with Cartesian in reverse merger
Nov 13, 2023 10:30am
Verve shows base editing works in humans—and sees stock sink
Nov 13, 2023 8:43am
Vor Bio's dual stem cell, ADC shows consistent engraftment
Nov 9, 2023 4:10pm
Trio of biotechs toss programs to discard pile
Nov 9, 2023 11:23am
See more stories